Tyme Technologies (TYME) Peer Comparison

$0.31

$0.02 (8.07%)

As on 16-Sep-2022 16:00EDT

Market cap

$54 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.7

Div. Yield

0 %

Edit

	Tyme Technologies (TYME)	Turning Point Therapeutics (TPTX)
Market cap ($ Mln)	54	3,806
Revenue ($ Mln)	--	1
Net Profit ($ Mln)	-24.19	-342.31
Net Margin (%)	-6,313.55	-33,130.60
RoE (%)	-30.08	-39.18
Price to Earnings	--	--
Price-To-Book	0.72	4.80

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Tyme Technologies (TYME)	Turning Point Therapeutics (TPTX)
Operating Revenue	0.00	30.83
Cost of Revenue	--	--
Gross Profit	--	30.83
Operating Expenses	23.08	268.83
Operating Profit (EBIT)	-25.51	-238.00
Other Income	-1.66	--
Profit before Tax	-23.63	-236.55
Provision for Tax	--	--
Profit after Tax (Net Income)	-23.63	-236.55
Minority Interest	--	--
Consolidated Profit	-23.63	-236.55

Liabilities ($ Mln)

	Tyme Technologies (TYME)	Turning Point Therapeutics (TPTX)
Shareholder's Funds	80.08	954.43
Minority Interest	--	--
Non-Current Liabilities	0.55	1.95
Current Liabilities	7.39	47.09
Total Liabilities	88.02	1,003.46

Assets ($ Mln)

	Tyme Technologies (TYME)	Turning Point Therapeutics (TPTX)
Non-Current Assets	9.12	11.00
Current Assets	78.90	992.46
Total Assets	88.02	1,003.46
Total Debt*	0.04	5.58
Net Current Assets	71.51	945.37

Cashflow ($ Mln)

	Tyme Technologies (TYME)	Turning Point Therapeutics (TPTX)
Cash From Operating Activities	-21.24	-153.89
Cash Flow from Investing Activities	-72.54	5.46
Cash from Financing Activities	0.01	24.00
Net Cash Inflow / Outflow	80.82	--

Ratios

Profitability Ratios

	Tyme Technologies (TYME)	Turning Point Therapeutics (TPTX)
ROCE (%)	-25.96	-22.81
ROE (%)	-25.98	-22.92
ROA (%)	-23.83	-22.11
EBIT Margin (%)	--	--
Net Margin (%)	1,740.86	-767.30
Cash Profit Margin (%)	--	--

Growth Ratios

	Tyme Technologies (TYME)	Turning Point Therapeutics (TPTX)
Revenue Growth (%)	--	0.23
EBIT Growth (%)	--	--
Net Profit Growth (%)	18.47	-50.39
EPS Growth (%)	0.36	-0.26
Book Value Growth (%)	--	--

Valuation Ratios

	Tyme Technologies (TYME)	Turning Point Therapeutics (TPTX)
Price / Earnings	-2.55	-9.88
Price / Book Value	0.75	2.45
Dividend Yield (%)	--	--
EV/EBITDA	0.62	-5.85
Market Cap ($ Cr)	--	--

Solvency Ratios

	Tyme Technologies (TYME)	Turning Point Therapeutics (TPTX)
Debt to Equity	0.00	0.01
Short term debt to equity ratio	0.00	0.00
Current Ratio	10.68	21.08
Quick Ratio	--	--
Interest Coverage	-363.21	--

Operating Efficiency Ratios

	Tyme Technologies (TYME)	Turning Point Therapeutics (TPTX)
Debtors to sales (%)	--	--
Asset Turnover	0.00	0.03
Receivable days	--	--
Inventory Days	--	--
Payable days	--	--
Cash Conversion Cycle	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly